HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.

Abstract
The success of autologous bone marrow transplantation (ABMT) in acute leukemia (AL) in complete remission (CR) is limited by the high relapse rate. It is generally accepted that minimal residual disease (MRD) plays a major role in determining the relapse of disease. In our study we investigated in adult acute leukemia and in chronic myelogenous leukemia (CML), the efficacy of ex vivo marrow purging with mafosfamide (an in vitro derivative of cyclophosphamide). We also describe an improved purging approach ("programmed method") based on the evaluation of sensitivity to the drug measured in each individual patient prior to ABMT. The analysis of clinical data in terms of disease-free survival (DFS) shows that the "programmed method" gives significantly better results than those obtained using the standard dose of mafosfamide (80% DFS in 18 AL patients vs. 44% in 33 ANLL patients and 33% in 56 ALL patients). The evaluation of the CR to purging interval in ALL and ANLL shows that a period of greater than 6 months is necessary to obtain longer DFS. Considering pre-transplant regimens, busulfan-cyclophosphamide is more effective in ANLL, and cyclophosphamide-fractionated total body irradiation is the best treatment for ALL. The studies using mafosfamide marrow purging in CML demonstrate that the drug is able to achieve a decrease of the Ph1+ marker. Three patients who showed conversion of this cytogenetic marker have been autografted with interesting clinical results.
AuthorsV Rizzoli, L Mangoni
JournalProgress in clinical and biological research (Prog Clin Biol Res) Vol. 333 Pg. 21-36; discussion 37-8 ( 1990) ISSN: 0361-7742 [Print] United States
PMID2308982 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • mafosfamide
  • Cyclophosphamide
Topics
  • Adult
  • Antineoplastic Agents (therapeutic use)
  • Bone Marrow (drug effects)
  • Bone Marrow Transplantation (methods)
  • Cyclophosphamide (analogs & derivatives, therapeutic use)
  • Humans
  • Leukemia (therapy)
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy)
  • Leukemia, Myeloid, Acute (therapy)
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: